Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Free Cash Flow (2016 - 2025)

Enanta Pharmaceuticals' Free Cash Flow history spans 14 years, with the latest figure at -$11.8 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 53.64% year-over-year to -$11.8 million; the TTM value through Dec 2025 reached -$18.5 million, up 80.92%, while the annual FY2025 figure was -$32.2 million, 66.74% up from the prior year.
  • Free Cash Flow reached -$11.8 million in Q4 2025 per ENTA's latest filing, up from -$18.0 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $27.4 million in Q2 2025 to a low of -$36.7 million in Q4 2022.
  • Average Free Cash Flow over 5 years is -$19.3 million, with a median of -$21.0 million recorded in 2021.
  • Peak YoY movement for Free Cash Flow: crashed 456.08% in 2022, then skyrocketed 228.5% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$13.6 million in 2021, then tumbled by 169.33% to -$36.7 million in 2022, then surged by 30.65% to -$25.5 million in 2023, then decreased by 0.31% to -$25.5 million in 2024, then skyrocketed by 53.64% to -$11.8 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Free Cash Flow are -$11.8 million (Q4 2025), -$18.0 million (Q3 2025), and $27.4 million (Q2 2025).